To include your compound in the COVID-19 Resource Center, submit it here.

Actonel risedronate regulatory update

FDA's Reproductive Health Drugs and Drug Safety and Risk Management advisory committees are scheduled to meet on Sept. 9 to discuss the risks and benefits of bisphosphonates for long-term use to

Read the full 316 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE